Current Issues of Pharmacy and Medical Sciences

The influence of proteasome inhibitor on the expression of cardiomyocytes damage markers after incubation with doxorubicin

Curr Issues Pharm Med Sci., Vol. 27, No. 2, Pages 88-91

Sylwia Tereszkiewicz1, Włodzimierz Matysiak2, Sławomir Mandziuk3, Agnieszka Korga1,  Małgorzata Oleksiejuk4,
Marcin Hejna5, Agnieszka Korobowicz-Markiewicz6, Magdalena Iwan1, Jarosław Dudka1

1 Independent Medical Biology Unit, Medical University of Lublin, Jaczewskiego 8, 20-097 Lublin, Poland
2 Department of Histology and Embryology, Medical University of Lublin, Radziwillowska 11, 20-080 Lublin, Poland

Department of  Pneumology Oncology and Alergology, Medical University of Lublin, Poland

4 IMMUNIQ Beata Solon-Gogol, Sasiedzka 1, 44-240 Zory, Poland
5 Regional Dental Clinic Independent Public Health Care, Lubartowska 58, Lublin, Poland
6 Department of Paediatric Pulmonology and Rheumatology, Medical University of Lublin, W. Chodzki, 20-093 Lublin, Poland

DOI: 10.2478/cipms-2014-0020



The aim of the study was to verify the thesis that the cardiotoxic effects of doxorubicin are connected with activation of the ubiquitin – proteasome pathway followed by protein degradation. The expression of myocardial damage markers - fatty acid binding protein (H-FABP) and brain natriuretic peptide (BNP) was evaluated in rat fetal cardiomyocytes simultaneously treated with doxorubicin and the proteasome inhibitor - bortezomib. The level of H-FABP and BNP protein under the influence of doxorubicin was decreased below the detection threshold with unchanged (H-FABP) or elevated (BNP) mRNA expression level. Against the expectations, the inhibitor of proteasome did not abolish this effect. The observed abnormal expression of BNP and H-FABP protein after doxorubicin treatment makes their diagnostic significance in anthracycline cardiotoxicity questionable.


Full text


doxorubicin, BNP, H-FABP, proteasom


  1. Adams J.: Development of the Proteasome Inhibitor PS-341. The Oncologist, 7, 9, 2002.
  2. Aihara Y. et al.: Doxorubicin Represses CARP Gene Transcription Through the Generation of Oxidative Stress in Neonatal Rat Cardiac Myocytes: Possible Role of Serine/Threonine Kinase – dependent Pathways. J. Mol. Cell Cardiol., 32, 1401, 2000.
  3. Batheja R. et al.: Paradoxical decrease in plasma N-terminal-proBNP (NTproBNP) levels in patients receiving doxorubicin chemotherapy and declining left ventricular ejection fraction. J. Am. Coll. Cardiol., 47, 66A, 2006.
  4. Chen S., Garami M., Gardner D. G.: Doxorubicin Selectively Inhibits Brain Versus Atrial Natriuretic Peptide Gene Expression in Cultured Neonatal Rat Myocytes. Hypertension, 34, 1223, 1999.
  5. Dudka J.: The role of reactive oxygen and nitrogen species in calcium and iron homeostasis dysregulation in anthracycline cardiotoxicity. Postepy Hig. Med. Dosw, 60, 241, 2006.
  6. Dudka J. et al.: The diagnosis of anthracycline-induced cardiac damage and heart failure. Postepy Hig. Med. Dosw , 63, 225, 2009.
  7. Hacihanefioglu A., Tarkun P., GonulluE.: Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int. J. Hematol., 88, 219, 2008.
  8. Hedhli N., Depre Ch.: Proteasome inhibitors and cardiac cell growth. Cardiovasc. Res., 85, 321, 2010.
  9. Korga A. et al.: The redox imbalance and the reduction of contractile protein content in rat hearts administered with L-thyroxine and Doxorubicin. Oxid. Med. Cell Longev., 681367, 2012.
  10. Liu J. et al.: A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome. Am. J. Physiol. Heart Circ. Physiol., 295, H2541, 2008.
  11. Lyu Y. L. et al.: TopoisomeraseIIb-Mediated DNA Double-Strand Breaks: Implications in Doxorubicin Cardiotoxity and Prevention by Dexrazoxane. Cancer Res., 67, 8839, 2007.
  12. Minotti G. et al.: Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxity. Pharmacol. Rev., 56, 185, 2004.
  13. Pichon M. F. et al.: Drug – induced Cardiotoxity Studied by Longitudinal B-Type Natriuretic Peptide Asays and Radionuclide Ventryculography. In Vivo, 19, 567, 2005.
  14. Ranek M. J., Wang X.: Activation of the Ubiquitin Proteasome System in Doxorubicin Cardiomyopathy. Curr. Hypertens. Rep., 11, 389, 2009.
  15. Sayed-Ahmad M. M. et al.: Protection by L-Carnitine Against the Inhibition of Gene Expression of Heart Fatty Acid Binding Protein by Chronic Administration of Doxorubicin. Journal of the Egyptian Nat. Cancer Inst., 4, 275, 2000.
  16. Sayed-Ahmed M. M. et al.: Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model. Eur. J. Pharmacol., 640, 143, 2010.
  17. Sun Y. et al.: B-Type Natriuretic Peptide-Induced Cardioprotection against Reperfusion Is Associated with Attenaution of Mitochondrial Permeability Transition. Biol. Pharm. Bull, 32, 1545, 2009.
  18. Szuławska A., Czyż M.: Molecular mechanisms of anthracyclines action. Postepy Hig. Med. Dosw., 60, 78, 2006.
  19. Tsutsui H., Kinugawa S., Matsushima S.: Oxidative Stress and Mitochondrial DNA Damage in Heart Failure”,Circ. J., Suppl Am, A-31, 2008.
  20. Voortman J., GiacconeG.: Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer, 6, 129, 2006.


April 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30